Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress of antiangiogenesis in treatment of gastric carcinoma

( views:184, downloads:72 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 5

DOI:: 10.3969/j.issn.1009-3079.2007.05.001

Key Word:: 胃癌;新生血管;综合治疗

Abstract：血管生成为肿瘤生长提供了营养,促进了肿瘤迅速增长,同时也使肿瘤细胞进入血液循环,促进了转移.抑制血管生成能显著抑制肿瘤的生长及转移,在胃癌的各种治疗实验已初步显示良好的应用前景,有望成为胃癌治疗的新方法.

Reference

[1]陈林莺,张声,林建银,等.促血管生成素-2对胃癌血管生成的双向效应[J].2004,(3).
[2]王宁,王斌,王雅杰.Avastin对胃癌裸鼠原位移植模型血管生成的影响[J].2006,(9).
[3]孙为豪,孙运良,方仁年,等.环氧化酶-2在胃癌组织中的表达及其与血管生成的关系[J].2005,(4).
[4]陈金联,陆金来,陈明祥,等.N-去硫酸肝素对SCID小鼠胃癌血管生成和VEGF表达的影响[J].2005,(22).
[5]吕晓君,毛晓韵,李锦毅,等.利用组织芯片技术研究COX-2在胃癌中的表达及其与血管生成的关系[J].2006,(6).
[6]刘飞德,陈凛,李基业.胃癌组织促红细胞生成素受体表达与血管生成的关系及意义[J].2006,(2).
[7]王天宝,吴小鹏,张维东,等.重组人内皮抑素对裸鼠胃癌瘤株生长的影响[J].2004,(4).
[8]蒋晓婷,陶厚权,邹寿椿.血管生成抑制剂SU6668对SCID鼠胃癌生长和转移抑制的作用[J].2006,(4).
[9]王升,吴本俨,尤纬缔.胃癌组织血管内皮生长因子表达对胃癌生物学行为的影响[J].2005,(6).
[10]李建生,张金平,刘升云.环氧合酶-2抑制剂对人胃癌细胞株的作用及机制探讨[J].2005,(2).
[11]张国锋,王元和,王强,等.SU5416抑制胃癌生长和肝转移的实验研究[J].2002,(4).
[12]徐美虹,吴开春,吴汉平,等.尼美舒利对胃癌抑制作用的实验研究[J].2003,(3).
[13]孙波,吴云林,王升年,等.舒林酸诱导人肝细胞癌凋亡及对环氧合酶-2和Bcl-2蛋白表达的影响[J].2002,(6).
[14]周红凤,吴瑾,王翠华,等.胃癌组织与血清中VEGF和bFGF的表达意义[J].2006,(21).
[15]樊晓明,郑发寿,刘红燕,等.环氧合酶-2特异抑制剂诱导胃癌细胞凋亡的机制研究[J].2005,(3).
[16]徐卫国,张力建,谢玉泉.血管内皮生长因子在原发性食管鳞状细胞癌中的表达及意义[J].2001,(14).
[17]王天宝,董文广,李兆亭.重组人内皮抑素联合应用5氟脲嘧啶对胃癌裸鼠移植瘤的影响[J].2005,(5).
[18]骞爱荣,赵俊生,商澎,等.血管内皮生长因子和血管生成与胃癌发展的关系[J].2003,(12).
[19]王钧,吴开春,张德新,等.人血管生成素-1基因转染对胃癌细胞体内致瘤力及血管生成的影响[J].2005,(2).
[20]张真真,张声,林建银,等.促血管生成素及其受体的异常表达与胃癌血管生成的关系[J].2006,(4).
[21]Kemal, Kismet,M Turan, Akay,Osman, Abbasoglu,etc.Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.[J].2004,28(2).
[22]O'Reilly,MS,Pirie,Shepherd-S,Lane,WS,etc.Antiangiogenic activity of the cleaved conformation of the serpin antithrombin (see comments)[J].1999,285(5435).
[23]Maehara Y,Shibahara K,Oda S,etc.Clinical significance of vascular endothelial growth factor expression in gastric cancer.[J].2002,21(1).
[24]Chung YS,Onoda N,Ogawa Y,etc.Tumor angiogenesis as a predictor of recurrence in gastric carcinoma.[J].1995,13(2).
[25]Liang C,Shawver LK,Shaheen RM,etc.Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.[J].2000,15(1).
[26]P C, Maisonpierre,C, Suri,P F, Jones,etc.Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.[J].1997,277.
[27]Holash J,Wiegand SJ,Yancopoulos GD.New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.[J].1999,18(38).
[28]Abbruzzese JL.A phase I surrogate endpoint study of SU6668 in patients with solid tumors.[J].2004,22(4).
[29]H L, Kong,R G, Crystal.Gene therapy strategies for tumor antiangiogenesis.[J].1998,90.
[30]Yanoma S,Motohashi H,Yoshikawa T,etc.Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci.[J].2000,47(31).
[31]Kari Alitalo,Tanja Veikkola.Dual Role of Ang2 in Postnatal Angiogenesis and Lymphangiogenesis[J].2002,3(3).
[32]Thorpe PE,Brekken RA.Vascular endothelial growth factor and vascular targeting of solid tumors.[J].2001,21(6B).
[33]R, Lucas,L, Holmgren,I, Garcia,etc.Multiple forms of angiostatin induce apoptosis in endothelial cells.[J].1998,92.
[34]Zondor SD,Medina PJ.Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.[J].2004,38(7).
[35]Michael S. O'Reilly,Lars Holmgren,Yuen Shing,etc.Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma[J].1994,79(2).
[36]Harlozinska A.Progress in molecular mechanisms of tumor metastasis and angiogenesis.[J].2005,25(5).
[37]Ito R,Zhang J,Zhu X,etc.Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma.[J].2003,442(6).
[38]Michael S O'Reilly,Thomas Boehm,Yuen Shing,etc.Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth[J].1997,88(2).
[39]Radtke F,Aguet M,Ryan AM,etc.VEGF is required for growth and survival in neonatal mice.[J].1999,126(6).
[40]M A, Lafleur,P A, Forsyth,S J, Atkinson,etc.Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity.[J].2001,282(2).
[41]Nakamura S,Tanaka T,Kaneko T,etc.Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.[J].2003,94(1).
[42]Maragoudakis M,Li WW,Thompson WD.The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies.[J].2000,190(3).
[43]Kuramoto H,Watanabe J,Akaboshi M,etc.Immunohistochemical study on VEGF expression in endometrial carcinoma--comparison with p53 expression, angiogenesis, and tumor histologic grade.[J].2001,127(11).
[44]Berry JA,Shoher A,Lucci A,etc.COX-2 overexpression increases motility and invasion of breast cancer cells.[J].2005,26(5).
[45]I H, Chaudhry,D G, O'Donovan,P E, Brenchley,etc.Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.[J].2001,39(4).